EA201070200A1 - Композиции, содержащие пневмококковые антигены - Google Patents

Композиции, содержащие пневмококковые антигены

Info

Publication number
EA201070200A1
EA201070200A1 EA201070200A EA201070200A EA201070200A1 EA 201070200 A1 EA201070200 A1 EA 201070200A1 EA 201070200 A EA201070200 A EA 201070200A EA 201070200 A EA201070200 A EA 201070200A EA 201070200 A1 EA201070200 A1 EA 201070200A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pneumococcal
polypeptides
compositions containing
antigens
vaccines
Prior art date
Application number
EA201070200A
Other languages
English (en)
Other versions
EA018137B1 (ru
Inventor
Клаудио Донати
Алессандро Муцци
Вега Масиньяни
Фабио Баньоли
Паоло РУДЖЕРО
Микеле Барокки
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201070200A1 publication Critical patent/EA201070200A1/ru
Publication of EA018137B1 publication Critical patent/EA018137B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Авторы полагают, что для эффективной вакцины против Streptococcus pneumoniae может требоваться несколько антигенных компонентов, и поэтому они идентифицировали различные сочетания пневмококковых полипептидов для использования при иммунизации. Также авторы идентифицировали некоторые пневмококковые полипептиды, которые могут быть полезны в качестве отдельных антигенов. Эти полипептиды необязательно можно использовать в сочетании с пневмококковыми сахаридами. Антигены можно использовать в пневмококковых вакцинах, но их также можно использовать в качестве компонентов в вакцинах для иммунизации против нескольких патогенов.
EA201070200A 2007-08-01 2008-08-01 Композиции, содержащие пневмококковые антигены EA018137B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0714963.6A GB0714963D0 (en) 2007-08-01 2007-08-01 Compositions comprising antigens
US96686607P 2007-08-29 2007-08-29
PCT/IB2008/002866 WO2009016515A2 (en) 2007-08-01 2008-08-01 Compositions comprising pneumococcal antigens

Publications (2)

Publication Number Publication Date
EA201070200A1 true EA201070200A1 (ru) 2010-08-30
EA018137B1 EA018137B1 (ru) 2013-05-30

Family

ID=38529101

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070200A EA018137B1 (ru) 2007-08-01 2008-08-01 Композиции, содержащие пневмококковые антигены

Country Status (20)

Country Link
US (2) US20110243976A1 (ru)
EP (2) EP2572726B1 (ru)
JP (2) JP2010535025A (ru)
CN (2) CN101801409A (ru)
AP (1) AP2010005173A0 (ru)
AU (1) AU2008281438A1 (ru)
BR (1) BRPI0813892A2 (ru)
CA (1) CA2695169A1 (ru)
CO (1) CO6260103A2 (ru)
CY (1) CY1117689T1 (ru)
DK (1) DK2572726T3 (ru)
EA (1) EA018137B1 (ru)
ES (1) ES2580957T3 (ru)
GB (1) GB0714963D0 (ru)
HR (1) HRP20160685T1 (ru)
HU (1) HUE029670T2 (ru)
PL (1) PL2572726T3 (ru)
PT (1) PT2572726T (ru)
SI (1) SI2572726T1 (ru)
WO (1) WO2009016515A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2623174C2 (ru) * 2011-01-20 2017-06-22 Дженоцея Байосайенсиз, Инк. Вакцины и композиции против streptococcus pneumoniae

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
BRPI0909664A2 (pt) * 2008-03-17 2019-09-24 Intercell Ag peptídios protetores contra s. pneumoniae e composições, métodos e usos relacionados com os mesmos
EP2218457B1 (en) * 2009-02-16 2011-09-07 Karlsruher Institut für Technologie CD44v6 peptides as inhibitors of bacterial infections
EP2437777B1 (en) * 2009-06-01 2014-09-17 Novartis AG COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES
US10105412B2 (en) 2009-06-29 2018-10-23 Genocea Biosciences, Inc. Vaccines and compositions against Streptococcus pneumoniae
EP2475385A1 (en) * 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
CN102939105B (zh) * 2009-12-22 2016-11-16 赛诺菲巴斯德有限公司 免疫原性组合物和相关的方法
WO2011112906A2 (en) 2010-03-12 2011-09-15 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
PT2591114T (pt) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Imunização de mamíferos de grande porte com doses baixas de arn
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
BR112013000392B8 (pt) 2010-07-06 2022-10-04 Novartis Ag Composição farmacêutica contendo partícula de distribuição semelhante a vírion para moléculas de rna autorreplicantes e seu uso
US20130171241A1 (en) 2010-07-06 2013-07-04 Novartis Ag Liposomes with lipids having an advantageous pka-value for rna delivery
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
WO2012025873A2 (en) 2010-08-23 2012-03-01 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
ES2935009T3 (es) 2010-08-31 2023-03-01 Glaxosmithkline Biologicals Sa Liposomas pegilados para la administración de ARN que codifica para inmunógeno
EP2611420B1 (en) 2010-08-31 2019-03-27 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
JP5976652B2 (ja) 2010-09-10 2016-08-24 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
AU2011316707A1 (en) 2010-10-11 2013-05-09 Novartis Ag Antigen delivery platforms
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
KR20230006042A (ko) * 2011-04-29 2023-01-10 셀렉타 바이오사이언시즈, 인크. 항체 반응을 감소시키기 위한 관용원성 합성 나노운반체
ES2864765T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Proteína de unión a biotina modificada, proteínas de fusión de la misma y aplicaciones
EP4014966A1 (en) 2011-07-06 2022-06-22 GlaxoSmithKline Biologicals S.A. Liposomes having useful n:p ratio for delivery of rna molecules
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
EP3508220A1 (en) 2011-08-31 2019-07-10 GlaxoSmithKline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding rna
CN108424464A (zh) * 2011-10-05 2018-08-21 洛克菲勒大学 二聚噬菌体溶素
CA2854934A1 (en) * 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP3485906A1 (en) 2012-03-09 2019-05-22 Pfizer Inc Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
AU2013320313B2 (en) 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles
KR20140075196A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
AU2014214844B2 (en) * 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US10124065B2 (en) 2013-03-08 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
CN110841067A (zh) 2013-05-03 2020-02-28 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
KR20180099912A (ko) 2013-09-08 2018-09-05 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
ES2774968T3 (es) 2013-12-19 2020-07-23 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
ES2908827T3 (es) 2013-12-19 2022-05-04 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
JP6778175B2 (ja) 2014-07-16 2020-10-28 ノバルティス アーゲー 脂質ナノ粒子ホスト中に核酸を封入する方法
US10125092B2 (en) 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CN107073091A (zh) 2014-09-07 2017-08-18 西莱克塔生物科技公司 用于减弱外显子跳读抗病毒转移载体免疫应答的方法和组合物
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
CN104844712B (zh) * 2015-04-03 2019-06-28 长春百克生物科技股份公司 肺炎链球菌蛋白抗原及其制备方法和应用
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CA3008042A1 (en) 2015-12-10 2017-06-15 National Research Council Of Canada Lipidated streptococcus pneumoniae antigen compositions, methods of preparation and use
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
BR112019018748A2 (pt) 2017-03-11 2020-04-07 Selecta Biosciences Inc métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
AU2018243910A1 (en) 2017-03-28 2019-11-14 The Children's Medical Center Corporation A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
GB201705750D0 (en) 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd Peptide ligase and use therof
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN111132691A (zh) 2017-06-10 2020-05-08 创赏有限公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
US11612647B2 (en) 2017-06-23 2023-03-28 University Of Maryland, Baltimore Immunogenic compositions
JP2021535921A (ja) 2018-09-12 2021-12-23 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
WO2023021427A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
CN114507658B (zh) * 2022-04-02 2022-07-05 深圳瑞德林生物技术有限公司 酶共表达系统及其在合成唾液酸的应用
WO2023236878A1 (zh) * 2022-06-07 2023-12-14 北京大学第一医院 包含IgA蛋白酶截短体的融合蛋白及其用途
WO2024006863A1 (en) 2022-06-30 2024-01-04 Precision NanoSystems ULC Lipid nanoparticle formulations for vaccines
CN117736279A (zh) * 2023-04-21 2024-03-22 华中农业大学 胸膜肺炎放线杆菌的三个候选抗原及其应用

Family Cites Families (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
CA2005704C (en) 1988-12-16 2003-02-11 James C. Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
US6716432B1 (en) 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
CA2063271A1 (en) 1989-07-14 1991-01-15 Subramonia Pillai Cytokine and hormone carriers for conjugate vaccines
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
AU657111B2 (en) 1990-12-20 1995-03-02 Dana-Farber Cancer Institute Control of gene expression by ionizing radiation
SG46492A1 (en) 1991-03-01 1998-02-20 Minnesota Mining & Mfg 1-Substituted 2-substituted 1H-imidazo [4,5-c] quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION.
UA40597C2 (ru) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинная композиция, способ лечения млекопитающих, больных или восприимчивых к инфекции, способ лечения млекопитающих, больных на рак, способ получения вакцинной композиции, композиция адъювантов
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
EP0695169B1 (en) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
ATE195735T1 (de) 1993-07-15 2000-09-15 Minnesota Mining & Mfg Imidazo (4,5-c)pyridin-4-amine
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
EP0814154B1 (en) 1993-09-15 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ATE314482T1 (de) 1993-10-25 2006-01-15 Canji Inc Rekombinante adenoviren-vektor und verfahren zur verwendung
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
ES2149955T3 (es) 1993-11-16 2000-11-16 Skyepharma Inc Vesiculas con liberacion controlada de sustancias activas.
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU2585395A (en) 1994-05-09 1995-11-29 Chiron Corporation Retroviral vectors having a reduced recombination rate
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US20020028215A1 (en) * 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
AU6909098A (en) 1996-10-31 1998-05-22 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6764686B2 (en) 1997-07-21 2004-07-20 Baxter International Inc. Modified immunogenic pneumolysin compositions as vaccines
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
CA2320223A1 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
EP1073450A4 (en) 1998-04-23 2003-04-23 Uab Research Foundation PNEUMOCOCCAL SURFACE PROTEIN C (PSPC), EPITOPIC REGIONS, SELECTION OF CORRESPONDING STRES AND USES
CA2330610A1 (en) 1998-05-07 1999-11-11 Corixa Corporation Adjuvant composition and methods for its use
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030134407A1 (en) * 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
CN1318103A (zh) * 1998-07-27 2001-10-17 微生物技术有限公司 肺炎链球菌的核酸和蛋白质
ATE361365T1 (de) 1998-07-27 2007-05-15 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
CA2355364C (en) 1998-12-21 2014-03-18 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
ATE276199T1 (de) 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
AR022963A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Biolog Vacuna
CN100379758C (zh) 1999-03-26 2008-04-09 科特克斯(Om)有限公司 肺炎链球菌抗原
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
AU777856B2 (en) 1999-06-10 2004-11-04 Human Genome Sciences, Inc. Streptococcus pneumoniae proteins and vaccines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
CA2383413A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
NZ517929A (en) 1999-09-25 2004-02-27 Univ Iowa Res Found Immunostimulatory nucleic acids
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2001081380A2 (en) 2000-04-27 2001-11-01 Medimmune, Inc. Immunogenic pneumococcal protein and vaccine compositions thereof
AU2001287645A1 (en) 2000-07-20 2002-02-05 Hansa Medical Ab Fh-binding protein of streptococcus pneumiae
US6756383B2 (en) 2000-09-01 2004-06-29 Chiron Corporation Heterocyclic derivatives of quinolinone benimidazoles
ATE386736T1 (de) 2000-09-11 2008-03-15 Novartis Vaccines & Diagnostic Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2292632A3 (en) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
AU2001295795A1 (en) 2000-10-26 2002-05-06 Imperial College Innovations Ltd. Streptococcal genes
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0108079D0 (en) 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
CN1300165C (zh) 2001-11-27 2007-02-14 安那迪斯药品股份有限公司 3－β－呋喃核糖基噻唑并[4,5－d]嘧啶核苷及其应用
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
CA2480638C (en) 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
WO2003082183A2 (en) 2002-04-02 2003-10-09 Ben-Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
DE60313163T2 (de) 2002-06-11 2008-01-03 Glaxosmithkline Biologicals S.A. Immunogene zusammensetzungen
WO2003105769A2 (en) 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
JP2006501243A (ja) 2002-08-23 2006-01-12 カイロン コーポレイション グリコーゲンシンターゼキナーゼ３のピロールベースのインヒビター
WO2004020609A2 (en) * 2002-08-30 2004-03-11 Tufts University Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
CA2504938C (en) 2002-11-07 2011-10-11 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
ES2391770T3 (es) 2003-01-21 2012-11-29 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos de triptantrina para la potenciación inmune
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
AU2004230244B2 (en) * 2003-04-15 2011-09-22 Intercell Ag S. pneumoniae antigens
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
JP4646806B2 (ja) 2003-12-31 2011-03-09 スンギュンカン ユニバーシティ 組み換え肺炎球菌ＣｌｐＰ蛋白質を含むワクチン
CA2560969A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
KR20070008625A (ko) 2004-04-05 2007-01-17 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
KR20070122458A (ko) * 2005-02-11 2007-12-31 에이스 바이오사이언시즈 에이/에스 표재성 스트렙토코커스 뉴모니아 폴리펩티드
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
CA2610667A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
CA2816182C (en) 2005-12-22 2018-02-20 Glaxosmithkline Biologicals S.A. Pneumococcal polysaccharide conjugate vaccine
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
MX2008010604A (es) 2006-02-17 2009-03-05 Novartis Ag Purificacion y uso de pilosidades de streptococcus pneumoniae y proteinas pilosas.
EP2004225B1 (en) * 2006-03-22 2012-04-25 Novartis AG Regimens for immunisation with meningococcal conjugates
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
CA2854934A1 (en) * 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2623174C2 (ru) * 2011-01-20 2017-06-22 Дженоцея Байосайенсиз, Инк. Вакцины и композиции против streptococcus pneumoniae

Also Published As

Publication number Publication date
WO2009016515A2 (en) 2009-02-05
ES2580957T3 (es) 2016-08-30
CN104001165A (zh) 2014-08-27
PL2572726T3 (pl) 2016-12-30
EP2572726A1 (en) 2013-03-27
CA2695169A1 (en) 2009-02-05
US20140348868A1 (en) 2014-11-27
JP5838193B2 (ja) 2016-01-06
HUE029670T2 (en) 2017-03-28
GB0714963D0 (en) 2007-09-12
CO6260103A2 (es) 2011-03-22
HRP20160685T1 (hr) 2016-07-15
US20110243976A1 (en) 2011-10-06
AP2010005173A0 (en) 2010-02-28
SI2572726T1 (sl) 2016-08-31
WO2009016515A3 (en) 2009-08-13
CN101801409A (zh) 2010-08-11
DK2572726T3 (en) 2016-07-04
JP2010535025A (ja) 2010-11-18
CY1117689T1 (el) 2017-05-17
AU2008281438A1 (en) 2009-02-05
EP2572726B1 (en) 2016-05-04
BRPI0813892A2 (pt) 2017-05-09
CN104001165B (zh) 2018-08-14
EA018137B1 (ru) 2013-05-30
JP2014034578A (ja) 2014-02-24
PT2572726T (pt) 2016-08-05
EP2197484A2 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
EA201070200A1 (ru) Композиции, содержащие пневмококковые антигены
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
PH12021550318A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2021015775A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos.
BRPI0520330B8 (pt) adjuvante a base de ácido polinosínico-policitidílico
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
CO6751287A2 (es) Composición antigénetica de micobacteria
MX2011011505A (es) Vacuna neumococica y usos de la misma.
BRPI0915076A2 (pt) composições de vacina, composição imunogênica, método para expressão dos antígenos quiméricos de hpv-hbsag supramencionados, composição farmacêutica, método para ocasionar resposta de anticorpo protetor para composição antigênica e/ou resposta de célula t citotóxica, uso das formulações antigênicas supramencionadas.
PH12018502403A1 (en) Hiv vaccine formulation
MX2019008779A (es) Antigenos de pseudomonas y combinaciones de antigenos.
CO2018001985A2 (es) Polipéptidos mrka, anticuerpos y usos de los mismos
MX2018012270A (es) Novedosas formulaciones de vacuna neumococica.
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
CU23720A3 (es) Adyuvante basado en ácido poliinosínico-ácido policitidílico
CY1117230T1 (el) Συνθεσεις για ανοσοποιηση εναντι staphylococcus aureus

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU